Search

Your search keyword '"van den Bos, Willemien"' showing total 6 results
Start Over Author "van den Bos, Willemien" Journal bju international
6 results on '"van den Bos, Willemien"'

1. Salvage irreversible electroporation for radio‐recurrent prostate cancer – the prospective FIRE trial

Author

Blazevski, Alexandar, primary, Geboers, Bart, additional, Scheltema, Matthijs J., additional, Gondoputro, William, additional, Doan, Paul, additional, Katelaris, Athos, additional, Agrawal, Shikha, additional, Baretto, Daniela, additional, Matthews, Jayne, additional, Haynes, Anne‐Maree, additional, Delprado, Warick, additional, Shnier, Ron, additional, van den Bos, Willemien, additional, Thompson, James E., additional, Lawrentschuk, Nathan, additional, and Stricker, Phillip D., additional

Published
2023
Full Text
View/download PDF

5. Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project

Author

Muller, Berrend G., van den Bos, Willemien, Brausi, Maurizio, Cornud, Francois, Gontero, Paolo, Kirkham, Alexander, Pinto, Peter A., Polascik, Thomas J., Rastinehad, Ardeshir R., de Reijke, Theo M., de la Rosette, Jean J., Ukimura, Osamu, Villers, Arnauld, Walz, Jochen, Wijkstra, Hessel, Marberger, Michael, Electrical Engineering, Eindhoven University of Technology, Biomedical Diagnostics Lab, Graduate School, Urology, CCA -Cancer Center Amsterdam, and APH - Amsterdam Public Health

Subjects
Ablation Techniques, Male, Consensus, SDG 3 - Good Health and Well-being, Delphi Technique, Surveys and Questionnaires, focal therapy, multiparametric MRI, Humans, Prostatic Neoplasms, prostate cancer, Magnetic Resonance Imaging
Abstract

Objective To define the role of multiparametric MRI (mpMRI) for treatment planning, guidance and follow-up in focal therapy for prostate cancer based on a multidisciplinary Delphi consensus project. Materials and Methods An online consensus process based on a questionnaire was circulated according to the Delphi method. Discussion points were identified by literature research and were sent to the panel via an online questionnaire in three rounds. A face-to-face consensus meeting followed the three rounds of questions that were sent to a 48-participant expert panel consisting of urologists, radiologists and engineers. Participants were presented with the results of the previous rounds. Conclusions formulated from the results of the questionnaire were discussed in the final face-to-face meeting. Results Consensus was reached in 41% of all key items. Patients selected for focal therapy should have biopsy-proven prostate cancer. Biopsies should ideally be performed after mpMRI of the prostate. Standardization of imaging protocols is essential and mpMRIs should be read by an experienced radiologist. In the follow-up after focal therapy, mpMRI should be performed after 6 months, followed by a yearly mpMRI. mpMRI findings should be confirmed by targeted biopsies before re-treatment. No consensus was reached on whether mpMRI could replace transperineal template saturation biopsies to exclude significant lesions outside the target lesion. Conclusions Consensus was reached on a number of areas related to the conduct, interpretation and reporting of mpMRI for use in treatment planning, guidance and follow-up of focal therapy for prostate cancer. Future studies, comparing mpMRI with transperineal saturation mapping biopsies, will confirm the importance of mpMRI for a variety of purposes in focal therapy for prostate cancer.

Published
2013

6. Focal irreversible electroporation as primary treatment for localized prostate cancer.

Author

van den Bos, Willemien, Scheltema, Matthijs J., Siriwardana, Amila R., Kalsbeek, Anton M.F., Thompson, James E., Ting, Francis, Böhm, Maret, Haynes, Anne‐Maree, Shnier, Ron, Delprado, Warick, and Stricker, Phillip D.

Subjects
*PROSTATE cancer treatment, *QUALITY of life, *PATIENT safety, *FOLLOW-up studies (Medicine), *ELECTROPORATION
Abstract

Objectives To determine the safety, quality of life (QoL) and short-term oncological outcomes of primary focal irreversible electroporation (IRE) for the treatment of localized prostate cancer (PCa), and to identify potential risk factors for oncological failure. Patients and Methods Patients who met the consensus guidelines on patient criteria and selection methods for primary focal therapy were eligible for analysis. Focal IRE was performed for organ-confined clinically significant PCa, defined as high-volume disease with Gleason sum score 6 (International Society of Urological Pathology [ISUP] grade 1) or any Gleason sum score of 7 (ISUP grades 2-3). Oncological, adverse event (AE) and QoL outcome data, with a minimum of 6 months' follow-up, were analysed. Patient characteristics and peri-operative treatment variables were compared between patients with and without oncological failure on follow-up biopsy. Wilcoxon's signed rank test, Wilcoxon's rank sum test and the chi-squared test were used to assess statistically significant differences in paired continuous, unpaired continuous and categorical variables respectively. Results A total of 63 patients met all eligibility criteria and were included in the final analysis. No high-grade AEs occurred. QoL questionnaire analysis demonstrated no significant change from baseline in physical (P = 0.81), mental (P = 0.48), bowel (P = 0.25) or urinary QoL domains (P = 0.41 and P = 0.25), but there was a mild decrease in the sexual QoL domain (median score 66 at baseline vs 54 at 6 months; P < 0.001). Compared with baseline, a decline of 70% in prostate-specific antigen level (1.8 ng/mL, interquartile range 0.96-4.8 ng/mL) was seen at 6-12 months. A narrow safety margin (P = 0.047) and system errors (P = 0.010) were identified as potential early risk factors for in-field oncological failure. In-field and whole-gland oncological control on follow-up biopsies was 84% (38/45 patients) and 76% (34/45 patients); this increased to 97% (38/39 patients) and 87% (34/39 patients) when patients treated with a narrow safety margin and system errors were excluded. Conclusion Our data support the safety and feasibility of focal IRE as a primary treatment for localized PCa with effective short-term oncological control in carefully selected men. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results